BCL2 and head and neck cancer: Indeed, a recent publication has shown that NPC, an epithelial head and neck cancer associated with EBV that expresses high levels of BCL‐2 in 80% of cases, can be efficiently treated by a combination of ABT‐199 and S63845, an MCL‐1 inhibitor [37].